Literature DB >> 19632122

Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.

Carine Aubry1, A James Wilson, Daniel Emmerson, Emma Murphy, Yu Yam Chan, Michael P Dickens, Marcos D García, Paul R Jenkins, Sachin Mahale, Bhabatosh Chaudhuri.   

Abstract

We present the design, synthesis and biological activity of a new series of substituted 3-(2-(1H-indol-1-yl)ethyl)-1H-indoles and 1,2-di(1H-indol-1-yl)alkanes as selective inhibitors of CDK4/cyclin D1. The compounds were designed to explore the relationship between the connection mode of the indolyl moieties and their CDK inhibitory activities. We found all the above-mentioned designed compounds to be selective inhibitors of CDK4/cyclin D1 compared to the closely related CDK2/cyclin A, with IC(50) for the best compounds 10m and 13a being 39 and 37microm, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632122     DOI: 10.1016/j.bmc.2009.06.070

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.

Authors:  Alan P Kozikowski; Hendra Gunosewoyo; Songpo Guo; Irina N Gaisina; Richard L Walter; Ariel Ketcherside; Colleen A McClung; Andrew D Mesecar; Barbara Caldarone
Journal:  ChemMedChem       Date:  2011-07-05       Impact factor: 3.466

2.  An efficient microwave assisted synthesis of novel class of Rhodanine derivatives as potential HIV-1 and JSP-1 inhibitors.

Authors:  Sukanta Kamila; Haribabu Ankati; Edward R Biehl
Journal:  Tetrahedron Lett       Date:  2011-08-24       Impact factor: 2.415

3.  Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells.

Authors:  Yuan Sun; Ying-Xia Li; Hai-Jun Wu; Si-Hung Wu; Y Alan Wang; Dian-Zhong Luo; D Joshua Liao
Journal:  J Cancer       Date:  2011-01-08       Impact factor: 4.207

4.  Cyclin-dependent kinase 4 phosphorylates and positively regulates PAX3-FOXO1 in human alveolar rhabdomyosarcoma cells.

Authors:  Lingling Liu; Jing Wu; Su Sien Ong; Taosheng Chen
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

5.  Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.

Authors:  Muhammad Imtiaz Shafiq; Thomas Steinbrecher; Ralf Schmid
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

6.  Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.

Authors:  Taek-In Oh; Yoon-Mi Lee; Taek-Jin Nam; Young-San Ko; Shinmee Mah; Jinhee Kim; Younghoon Kim; Rallabandi Harikrishna Reddy; Young Jun Kim; Sungwoo Hong; Ji-Hong Lim
Journal:  Int J Mol Sci       Date:  2017-09-29       Impact factor: 5.923

7.  Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents.

Authors:  Maxim E Zhidkov; Moritz Kaune; Alexey V Kantemirov; Polina A Smirnova; Pavel V Spirin; Maria A Sidorova; Sergey A Stadnik; Elena Y Shyrokova; Dmitry N Kaluzhny; Oleg A Tryapkin; Tobias Busenbender; Jessica Hauschild; Tina Rohlfing; Vladimir S Prassolov; Carsten Bokemeyer; Markus Graefen; Gunhild von Amsberg; Sergey A Dyshlovoy
Journal:  Mar Drugs       Date:  2022-03-02       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.